Cocrystal Pharma Stock Price - COCP

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 0.77 ▲ 0.01 (1.68%)
Company Name Stock Ticker Symbol Market Type
Cocrystal Pharma Inc COCP NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.0273 3.74% 0.7573 0.77 0.711 0.711 0.73 19:24:30
Bid Price Ask Price Spread Spread % News
0.40 0.79 0.39 49.37% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
319 135,595 $ 0.740305 $ 100,382 194,881 0.3861 - 3.2491
Last Trade Time Type Quantity Stock Price Currency
16:30:42 67 $ 0.77 USD

Cocrystal Pharma Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 26.62M 35.15M $ -49.05M -1.75 - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Cocrystal Pharma News

Loading Messages....

Latest COCP Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical COCP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.63950.840.6111450.7101992325,8790.117818.42%
1 Month0.4690.840.4450.6187175244,3980.288361.47%
3 Months0.7430.840.38610.5764983176,8070.01431.92%
6 Months2.21992.950.38610.658470390,177-1.46-65.89%
1 Year2.923.24910.38610.840396150,278-2.16-74.07%
3 Years4.366.450.38612.0458,328-3.60-82.63%
5 Years4.366.450.38612.0458,328-3.60-82.63%

Cocrystal Pharma Description

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

Your Recent History
Cocrystal ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.